Search

Your search keyword '"Rupolo M"' showing total 161 results
Start Over Author "Rupolo M"
161 results on '"Rupolo M"'

18. EP-1246: Radiotherapy after autologous stem cell transplant in recurrent or refractory hodgkin's lymphoma

Author

Matrone, F., primary, Furlan, C., additional, Rupolo, M., additional, Ciancia, R., additional, Zanet, E., additional, Montante, B., additional, Navarria, F., additional, Palazzari, E., additional, Farina, E., additional, Bulian, P., additional, Mascarin, M., additional, De Paoli, A., additional, Franchin, G., additional, and Michieli, M., additional

Published
2018
Full Text
View/download PDF

19. The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma

Author

Furlan, C., primary, Michieli, M., additional, Bortolus, R., additional, Mascarin, M., additional, Avanzo, M., additional, Rupolo, M., additional, Zanet, E., additional, Filippi, A., additional, Tirelli, U., additional, and Trovo, M., additional

Published
2014
Full Text
View/download PDF

23. Linfoma di Hodgkin

Author

Zagonel, Mv, Corvo', RENZO GIACINTO, Rupolo, M., Spazzapan, S., Carbone, A., and Pinto, A.

Published
1999

31. Comparable Survival between HIV+ and HIV- Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Patients Undergoing an Autologous Peripheral Blood Stem Cell Transplantation (ASCT). A Retrospective Analysis of the EBMT Lymphoma Working Party.

Author

Diez-Martin, Jose L., primary, Balsalobre, Pascual, primary, Re, Alessandro, primary, Biron, Pierre, primary, Conde, Eulogio, primary, Rosselet, Anne, primary, Allione, Bernardino, primary, Espigado, Ildefonso, primary, Genet, Philippe, primary, Ribera, Josep-Maria, primary, Ferrant, Augustin, primary, Gillerm, Gaelle, primary, Meyer, Dirk, primary, Rupolo, M., primary, Varela, Rosario, primary, Hentrich, Marcus, primary, Hunter, Ann E., primary, Canals, Carmen, primary, Taghipour, Goli, primary, Serrano, David, primary, and Sureda, Anna, primary

Published
2007
Full Text
View/download PDF

36. Immunophenotypic clustering of B-Cell chronic lymphocytic leukemia (B-CLL) reveals a good prognosis disease subset characterized by the coordinated over-expression of CD62L, CD54, CD49c, CD25 And CD55

Author

Gattei, V., primary, Degan, M., additional, Russo, S., additional, Bomben, R., additional, Dal Bo, M., additional, Rupolo, M., additional, Buccisano, F., additional, Del Poeta, G., additional, Sonego, P., additional, and Zucchetto, A., additional

Published
2004
Full Text
View/download PDF

40. Long term cryopreservation in 5% DMSO maintains unchanged CD34+ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation.

Author

Abbruzzese, L., Agostini, F., Durante, C., Toffola, R. T., Rupolo, M., Rossi, F. M., Lleshi, A., Zanolin, S., Michieli, M., and Mazzucato, M.

Subjects
STEM cell transplantation, CRYOPRESERVATION of organs, tissues, etc., DIMETHYL sulfoxide, BLOOD platelets, CD34 antigen, GRANULOCYTES, TREATMENT effectiveness, HEMOGLOBINS, HEMATOLOGY
Abstract

Peripheral blood stem cell cryopreservation is associated with cell damage and decreased viability. We evaluated the impact of up to 10 years of cryopreservation (5% DMSO) on viability of CD34+ cells utilizing graft samples of consecutive patients (2002-2012) with different malignancies who underwent stem cell collection and transplantation. Viability of CD34+ cells from oncohaematological patients measured after 5 weeks (97·2 ± 0·6%) or after 9-10 years of cryopreservation (95·9 ± 0·5%) was unaffected. Haemoglobin, granulocyte and platelet recovery after transplantation of long-term cryopreserved grafts occurred within 8-13 days. CD34+ stem cells can be safely stored up to 9-10 years, without affecting cell viability and clinical effectiveness. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

41. Knowledge and skills needs for health professions about pharmacogenomics testing field.

Author

Di Francia, R., Valente, D., Catapano, O., Rupolo, M., Tirelli, U., and Berretta, M.

Abstract

Background: Promise in the future, a disease could be ranked into genetic categories, allowing bespoke tailoring of medicine to maximize therapeutic effects and to reduce the potential for adverse drug response. This new feature requires for health professionals to have competencies not only for the basic skills of their discipline, but also for the understanding on why, when, and how that knowledge should be applied to improve personalized therapies for their patients. Current opinion on basic competences of health professions includes knowledge and skills on two fundamental features: (1) genetics of disease, to allow the understanding and the identification of diseases associated to genetic variations, and to facilitate the development of new genomic tests; and (2) ethical, social and economical implications that are fundamental to identify those factors that might contribute to a successful integration of pharmacogenomics into international health and public policy. Aim: Briefly, we described (1) current knowledge on genetic variations that interact with therapies and the need to detect them; (2) the most common available methods for detecting mutations; and (3) ethical, social and economic issues related to pharmacogenetic testing and recording of genetic information (e.g., critical evaluation of the development of new tests, privacy, the current absence of public reimbursement, etc). Conclusions: These could be useful recommendations for academic institutions and educational programs to prepare health professionals with the necessary abilities for their future practice. [ABSTRACT FROM AUTHOR]

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results